Carregant...
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions st...
Guardat en:
| Publicat a: | Nat Rev Cancer |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5381938/ https://ncbi.nlm.nih.gov/pubmed/27079802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrc.2016.36 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|